Virax Biolabs Group Limited (VRAX) Income Statement
VRAX FY2026 at a glance
Fiscal year ended March 31, 2026 · U.S. dollarsVRAX revenue and net income
Where VRAX's revenue goes
FY2026Each bar shows an amount and its share of revenue. VRAX kept −40,439.1% of revenue as net income.
VRAX profit margins
VRAX growth rates
to FY2026| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +96.2% | +13.2% | −36.9% | — |
| Gross profit | — | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
VRAX quarterly EPS vs estimates
Virax Biolabs beat the analyst EPS estimate in 0 of the last 4 quarters.
VRAX income statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Revenue | $12,423 | $6,331 | $156,419 | $8,561 | $0 | $123,820 | $99,876 |
| Cost of revenue | $4,733 | $59,398 | $105,829 | $9,926 | $0 | $133,254 | $54,127 |
| Gross profit | $7,690 | −$53,067 | $50,590 | −$1,365 | $0 | −$9,434 | $45,749 |
| Research & development | $3.7M | $1.8M | $1.6M | $397,109 | $433,743 | $120,221 | $87,000 |
| Sales, general & admin | $2.7M | $4.3M | $4.6M | $5.3M | $1.3M | $514,883 | $609,993 |
| Total operating expenses | $6.4M | $6.1M | $6.5M | $5.7M | $1.7M | $635,104 | $696,993 |
| Operating income | −$6.4M | −$6.2M | −$6.5M | −$5.7M | −$1.7M | −$644,540 | −$651,244 |
| Interest expense | $61,772 | $58,179 | $26,878 | $15,468 | $15,438 | $28,643 | $90,690 |
| Income before taxes | −$5.9M | −$6.2M | −$6.7M | −$5.5M | −$1.7M | −$672,915 | −$739,464 |
| Income taxes | −$900,240 | −$136,661 | −$194,474 | −$271 | −$1.8M | −$666,469 | $61,667 |
| Net income | −$5.0M | −$6.1M | −$6.7M | −$5.5M | −$1.7M | −$650,984 | −$801,131 |
| EBITDA | −$5.4M | −$5.8M | −$6.6M | −$5.4M | −$750 | −$644,272 | $2,470 |
| EPS (diluted) | −$1.25 | −$0.92 | −$54.26 | −$76.87 | −$1.10 | −$0.06 | −$0.07 |
| Gross margin | 61.9% | −838.2% | 32.3% | −15.9% | — | −7.6% | 45.8% |
| Operating margin | −51,515.2% | −97,344.8% | −4,153.3% | −66,963.7% | — | −520.5% | −652.1% |
| Net margin | −40,439.1% | −95,739.2% | −4,304.8% | −63,748.3% | — | −525.8% | −802.1% |
| Jun '26 | Sep '25 | Jun '25 | Sep '24 | Jun '24 | Sep '23 | Mar '23 | Dec '22 | Sep '22 | Jun '22 | Mar '22 | Dec '21 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $12,423 | $1,608 | $1,378 | $4,953 | $79,919 | $76,500 | $2,801 | $2,801 | $5,760 | $0 | $0 | $30,955 |
| Cost of revenue | $4,733 | $217,022 | $47,971 | $11,427 | $39,847 | $65,982 | $4,284 | $4,284 | $5,642 | $99,940 | $99,940 | $33,313 |
| Gross profit | $7,690 | −$215,414 | −$46,593 | −$6,474 | $40,072 | $10,518 | −$1,483 | −$1,483 | $118 | −$192,805 | −$192,806 | −$2,358 |
| Research & development | $3.7M | $1.4M | $1.1M | $726,412 | $1.2M | $409,295 | $300,487 | $300,487 | $96,622 | $325,646 | $108,436 | $30,055 |
| Sales, general & admin | $2.7M | — | $2.2M | $2.1M | $2.3M | $2.3M | $4.0M | $4.0M | $1.3M | $841,293 | $328,438 | $143,020 |
| Total operating expenses | $6.4M | $2.4M | $3.2M | $2.9M | $3.8M | $2.7M | $4.3M | $4.3M | $1.4M | $1.2M | $436,686 | $173,143 |
| Operating income | −$6.4M | −$2.6M | −$3.3M | −$2.9M | −$3.8M | −$2.7M | −$4.3M | −$4.3M | −$1.4M | −$1.2M | −$433,420 | −$161,134 |
| Interest expense | $61,772 | $30,991 | $32,588 | $25,591 | $16,764 | $10,114 | $5,860 | $5,860 | $9,608 | $1,294 | $3,860 | $7,161 |
| Income before taxes | −$5.9M | −$2.6M | −$3.3M | −$2.9M | −$3.8M | −$2.9M | −$4.0M | −$4.0M | −$1.5M | −$1.2M | −$437,468 | −$168,229 |
| Income taxes | −$900,240 | −$273,594 | — | −$136,661 | −$1,031 | −$4,551 | −$4.3M | −$4.3M | −$1.5M | $16,647 | −$10,072 | −$5,549 |
| Net income | −$5.0M | −$2.3M | −$3.3M | −$2.8M | −$3.8M | −$2.9M | −$4.0M | −$4.0M | −$1.4M | −$1.2M | −$427,395 | −$162,680 |
| EBITDA | −$5.6M | −$2.4M | −$3.1M | −$2.7M | −$3.7M | −$2.7M | $294,070 | $294,070 | −$3,600 | −$1.2M | −$423,347 | −$155,585 |
| EPS (diluted) | — | −$0.49 | −$0.76 | −$0.89 | — | — | — | — | — | −$0.03 | — | — |
| Gross margin | 61.9% | −13,396.4% | −3,381.2% | −130.7% | 50.1% | 13.7% | −52.9% | −52.9% | 2.0% | — | — | −7.6% |
| Operating margin | −51,515.2% | −160,788.2% | −238,316.8% | −58,124.2% | −4,742.6% | −3,537.5% | −153,237.8% | −153,237.8% | −25,010.1% | — | — | −520.5% |
| Net margin | −40,439.1% | −145,446.0% | −239,827.3% | −55,651.7% | −4,784.7% | −3,803.5% | −143,301.8% | −143,301.8% | −25,062.7% | — | — | −525.5% |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in VRAX's financial statements (latest annual report filed July 6, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
VRAX financial results
In fiscal year 2026 (ended March 31, 2026), Virax Biolabs reported revenue of $0.0 million, up 96.2% from the year before. It had a net loss of $5.0 million, a net profit margin of −40,439.1%. Diluted earnings per share came to −$1.25. Over five years revenue grew at an average rate of −36.9% a year.
See the VRAX stock overview for the latest quote and news, or the VRAX chart for price history and technical indicators.
VRAX income statement FAQ
What is Virax Biolabs's annual revenue?
Virax Biolabs reported total revenue of $0.0 million for fiscal year 2026, which ended on March 31, 2026. That was up 96.2% from $0.0 million the previous year.
Is Virax Biolabs profitable?
No. Virax Biolabs reported a net loss of $5.0 million in fiscal 2026, a net profit margin of −40,439.1%; its operating margin was −51,515.2%.
What is Virax Biolabs's gross margin?
Virax Biolabs's gross margin was 61.9% in fiscal 2026: for every $100 of revenue, Virax Biolabs kept $62 after the direct cost of its products and services.
How much does Virax Biolabs spend on research and development?
Virax Biolabs spent $3.7 million on research and development in fiscal 2026, 30,092.2% of revenue.
How fast is Virax Biolabs growing?
Revenue grew −36.9% a year on average over the last five fiscal years, from $0.1 million to $0.0 million.
What are Virax Biolabs's earnings per share?
Virax Biolabs earned $-1.25 per diluted share in fiscal 2026, compared with $-0.92 a year earlier.
When does Virax Biolabs's fiscal year end?
Virax Biolabs's fiscal year ends in March. The latest annual report covers the year ended March 31, 2026 and was filed on July 6, 2026.